loading page

Radiofrequency Catheter Ablation of Premature Ventricular Contractions from the Mitral Annulus in Patients without Structural Heart Disease
  • +4
  • Yoshibumi Antoku,
  • Masao Takemoto,
  • Atsushi Tanaka,
  • Akihiro Masumoto,
  • Takahiro Mito,
  • Takafumi Ueno,
  • Takuya Tsuchihashi
Yoshibumi Antoku
Social Medical Corporation Steel Memorial Yawata Hospital
Author Profile
Masao Takemoto
Kyushu University Hospital
Author Profile
Atsushi Tanaka
Saiseikai Fukuoka General Hospital
Author Profile
Akihiro Masumoto
Fukuoka Kinen Hospital
Author Profile
Takahiro Mito
Hakujuji Hospital
Author Profile
Takafumi Ueno
Fukuoka Kinen Hospital
Author Profile
Takuya Tsuchihashi
Social Medical Corporation Steel Memorial Yawata Hospital
Author Profile

Abstract

INTRODUCTION: We previously reported the clinical benefits of radiofrequency catheter ablation (RFCA) of premature ventricular contractions (PVCs) from the right ventricular outflow tract or near His-bundle, which often can deteriorate clinical status and cause left ventricular (LV) dilation that develops into heart failure. This study aimed to evaluate the role of ablating PVCs per RFCA from a trans-interatrial septal approach in the LV dilation and clinical status in patients with PVCs from the mitral annulus (MA) (MA-PVCs) without structural heart disease. METHODS: The frequency of PVCs per the total heart beats by 24-h Holter monitoring, left ventricular ejection fraction (LVEF) and left ventricular end-diastolic (LVDd) and -systolic (LVDs) internal dimensions by echocardiography, New York Heart Association (NYHA) functional class, and serum brain natriuretic peptide (BNP) concentration in 22 patients with MA-PVCs were evaluated before and 6 months after RFCA. RESULTS: Before the RFCA, the patients with frequent (20% <) PVCs demonstrated a significantly reduced LVEF, enlarged LVDd and LVDs, deteriorated NYHA functional class, and elevated serum BNP concentration as compared to the subgroup with rare (≤ 20%) PVCs. Furthermore, ablating MA-PVCs readily produced an improvement in those abnormalities as compared to that before the RFCA. Interestingly, the MA-PVCs were successfully ablated from not only the ventricular side of the MA (68%) or coronary sinus (5%), but also the left atrial side of the MA (18%). CONCLUSIONS: RFCA produces clinical benefits in patients with MA-PVCs. Further, it may be necessary to initially consider a trans-interatrial septal approach to ablate these PVCs.